

# Proposed changes to IVD medical device classifications and definitions



Babak Latif

Senior Technical Evaluator and Policy Officer

Devices In Vitro Diagnostics Section (DIVDS)

Therapeutic Goods Administration (TGA)



Australian Government

Department of Health and Aged Care

Therapeutic Goods Administration

# Acknowledgement of Country

In the spirit of reconciliation, the Department of Health and Aged Care acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community.

We pay our respect to their Elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today



Australian Government

Department of Health and Aged Care  
Therapeutic Goods Administration

[tga.gov.au](https://www.tga.gov.au)

# Welcome

## Housekeeping



This webinar is being recorded for data analytics purposes only. The presentation will be shared in the upcoming weeks.



### **Closed captions are available**

Activate it with the speech bubble icon on the bottom left of your screen



### **Difficulties with sound?**

Check your settings located under **Audio & Video** located top of your screen

You can also call to join the webinar on the details below.

**Dial:** 02 9338 2221 (+61-2-9338-2221)

**Access code:** 2654 434 4991



Australian Government

Department of Health and Aged Care

Therapeutic Goods Administration



# Slido

## How to access and use Slido



### Through the Slido application in Webex



- Click on the Apps icon
  - Select Slido
- Open the Q&A tab to ask questions
- Live Poll (use survey tab when prompted)



### Using the QR code



Scan the QR code to access Slido from your mobile device



# Proposed changes to IVD medical device classifications and definitions



Babak Latif

Senior Technical Evaluator and Policy Officer

Devices In Vitro Diagnostics Section (DIVDS)

Therapeutic Goods Administration (TGA)



Australian Government

Department of Health and Aged Care

Therapeutic Goods Administration



# Today's showcase on the proposed changes to IVD medical device classifications and definitions consultation



## Background

- IVD medical device classification
- Proposed changes
- Why they are changing

## Overview of the consultation

- Our approach
- Benefits of proposed changes
- Impacts

## Q&A



Australian Government  
Department of Health and Aged Care  
Therapeutic Goods Administration

[tga.gov.au](https://tga.gov.au)

# What are the IVD medical device classifications?

## IVD medical device classification

Aus	EU	Examples	Risk
Class 1	Class A	<ul style="list-style-type: none"><li>Specimen collection containers</li><li>Microbiological culture media</li></ul>	No public health risk or low personal risk
Class 2	Class B	<ul style="list-style-type: none"><li>Pregnancy and fertility self-tests</li><li>Cholesterol tests</li></ul>	Low public health risk or moderate personal risk
Class 3	Class C	<ul style="list-style-type: none"><li>Tests to detect a sexually transmitted disease (e.g. chlamydia, gonorrhoea)</li><li>Human genetic tests</li></ul>	Moderate public health risk or high personal risk
Class 4	Class D	<ul style="list-style-type: none"><li>Blood donor screening tests for HIV</li><li>ABO blood grouping tests</li></ul>	High public health risk



See [Classification of IVD medical devices](#) for more information. These classification rules are written within Schedule 2A of the *Therapeutic Goods (Medical Devices) Regulations 2002*.



Australian Government  
Department of Health and Aged Care  
Therapeutic Goods Administration

# Approaches for the alignment



Australian Government  
Department of Health and Aged Care  
Therapeutic Goods Administration



## Proposed changes:

- ✓ Amend IVD classification rules and principles to align with the classification and implementation rules (Annex VIII) of the EU IVD Regulations (2017/746)
- ✓ Australian classification rules adopt certain terminology from EU to cover the new and emerging technologies and improve clarity on specific IVD terms currently not defined in the Australian regulations.
- Classification rule for **self-test** IVDs are **excluded**.



## Proposed NO changes:

- ✓ Australian classification rules and principles **already align** with the relevant EU classification.
- ✓ Australian classification for certain devices retained.



# Benefits



- Increase alignment between Australian and EU requirements
- Result in greater consistency in regulatory requirements of IVD medical devices
- Shorten the time for products to enter the Australian market
- Improve clarity and transparency
- Reduce public health and safety risks
- Increase consumer confidence in the regulation of IVD medical devices



# Proposed changes

A. Classification changes with **an impact** on approved IVDs



Australian Government  
Department of Health and Aged Care  
Therapeutic Goods Administration



# Proposed changes with impact

## A. Cancer tests

European IVD Regulation 2017/746	Current Australian regulation	Proposed amendments
2.3 Rule 3  Devices are classified as Class C if they are intended:  ----- (h) to be used in <b>screening</b> , diagnosis, or <b>staging</b> of cancer;	1.3 An IVD medical device is classified as a Class 3 IVD medical device or a Class 3 in-house IVD medical device if it is intended for any of the following uses: ----- (f)(iii) in the diagnosis of cancer	<b>The TGA proposes to include ‘screening’ and ‘staging’ in addition to ‘diagnosis of cancer’,</b> to ensure the classification is proportionate to the risk posed to the patient and this also aligns with the EU rule.

**Rationale:** IVD medical device used to detect cancer is appropriate to be classified as a Class 3 IVD medical device when used either for screening, diagnosis or staging as cancer is a life-threatening disease and poses a high personal risk.

**Impact:** The proposed change will result in re-classification of devices intended for cancer screening to Class 3 IVD.

**Examples:** faecal occult blood (FOB), total prostate specific antigen (PSA), Carcinoembryonic Antigen (CEA)



Australian Government  
Department of Health and Aged Care  
Therapeutic Goods Administration



# Proposed changes with impact

## B. Preliminary testing and monitoring devices

European IVD Regulation 2017/746	Current Australian regulation	Proposed amendments
No equivalent note.	Note for paragraph (f): An IVD medical device would be classified as Class 2 if: (a) a therapy decision would usually be made only after further investigation; or (b) the device is used for monitoring.	<b>The TGA proposes to remove ‘Note for paragraph (f)’</b> to ensure the classification is proportionate to the risk posed to the patient.

**Rationale:** The devices used for selective therapy and management, disease staging, and cancer diagnosis (Rule 1.3(f)) pose similar personal health risks when used for initial investigation or monitoring and should have consistent classification.

**Impact:** Re-classification of these devices, when used for preliminary testing or monitoring, to Class 3 IVD medical devices.

**Examples:** Immunohistology cell marker IVD medical devices



# Proposed changes with impact

## C. Devices used to manage life-threatening conditions

European IVD Regulation 2017/746	Current Australian regulation	Proposed amendments
2.3 Rule 3  Devices are classified as Class C if they are intended:	1.3 An IVD medical device is classified as a Class 3 IVD medical device or a Class 3 in-house IVD medical device if it is intended for any of the following uses:	<b>The TGA proposes to replace ‘life-threatening infectious disease’ with ‘life-threatening disease or condition’</b> to ensure the classification is proportionate to the risk posed to the patient and this also aligns with the EU rule.
(k) for management of patients suffering from a life-threatening <b>disease or condition</b> ;	(i) the management of patients suffering from a life-threatening <b>infectious</b> disease;	

**Rationale:** Life-threatening diseases and conditions, irrespective of whether they are infectious or non-infectious, pose a high personal health risk and are critical for patient management decision.

**Impact:** Re-classification of these devices to Class 3 IVD.

**Examples:** HbA1c and blood glucose tests, D-Dimer in patients with thrombotic disorders, monitoring anticoagulant therapy with PT (partial thromboplastin time)





# Proposed changes with impact

## D. Newborn screening devices

European IVD Regulation 2017/746	Current regulation	Australian	Proposed amendments
2.3 Rule 3  Devices are classified as Class C if they are intended:  (m) for screening for congenital disorders in new-born babies where failure to detect and treat such disorders could lead to life-threatening situations or severe disabilities.	No equivalent rule.		<b>The TGA proposes to adopt this rule</b> to ensure the classification is proportionate to the risk posed to the patient and this also aligns with the EU rule.

**Rationale:** An erroneous test result in newborn screening could lead to a failure to detect and treat such birth disorders, which could result in life-threatening situation or severe disability of the patient and hence pose a high personal health risk.

**Impact:** Re-classification of some non-genetic tests used for newborn screening of life-threatening conditions from Class 2 to Class 3.

**Examples:** HPLC for newborn screening of haemoglobinopathies, phenylketonuria (PKU) tests and tests for congenital hypothyroidism and congenital adrenal hyperplasia



Australian Government  
Department of Health and Aged Care  
Therapeutic Goods Administration



# Proposed changes with impact

## E. Control materials

European IVD Regulation 2017/746	Current Australian regulation	Proposed amendments
2.7 Rule 7  Devices which are controls <b>without a quantitative or qualitative assigned value</b> are classified as class B.	1.5 Despite clauses 1.1 to 1.4, an IVD medical device that is intended to be used as non-assay-specific quality control material is classified as a Class 2 IVD medical device or a Class 2 in-house IVD medical device.	<b>The TGA proposes to classify controls based on assigned values</b> to ensure the classification is appropriate to the current use and risks posed to the patient and this also aligns with the EU rule.

**Rationale:** Controls used for one assay (assay-specific), or multiple assays (non-assay-specific) where values are assigned by the manufacturer and not the user are used to monitor performance of devices of various classes and have similar risks as the devices therefore should be classified in the same class as the device.

**Impact:** Re-classification of some non-assay specific control materials with assigned values to Class 3 or 4 based on the associated IVD medical devices.

**Examples:** Control materials with assigned values used to verify the performance of HIV assays (Class 4), syphilis assays (Class 3), TSH assays (Class 2)



# Proposed changes with impact

## F. Instruments

European IVD Regulation 2017/746	Current Australian regulation	Proposed amendments
2.5 Rule 5  The following devices are classified as class A:  ----- (b) Instruments intended by the manufacturer specifically to be used for in vitro diagnostic procedures	1.6 (2) <b>Despite clauses 1.1 to 1.5</b> , the following IVD medical devices are classified as Class 1 IVD medical devices or Class 1 in-house IVD medical devices: ----- (a) an instrument, intended by the manufacturer, to be specifically used for in vitro diagnostic procedures;	<b>Remove ‘Despite clauses 1.1 to 1.5’ from statement 1.6 (2)</b> to ensure the classification is appropriate to the current use and risks posed to the patient and this also aligns with the EU rule.

**Rationale:** The reagents and kits associated with the instruments are classified and assessed based on their intended purpose. Hence, the instrument with an independent measuring function which does not use any additional reagents with critical characteristics should be classified based on its intended purpose and the risk posed.

**Impact:** Re-classification of some Class 1 instruments / analysers with an independent measuring function

**Examples:** Cell counting analysers, COVID breath analysers, instruments measuring blood gas, electrolytes, glucose via sensors, specific gravity measurements in urine analysis



# Proposed changes with impact

## G. Software

European IVD Regulation 2017/746	Current Australian regulation	Proposed amendments
Annex VIII, 1.4  Software, which drives a device or influences the use of a device, shall fall within the same class as the device. <b>If the software is independent of any other device, it shall be classified in its own right.</b>	Regulation 3.3 (5)  If a medical device is driven, or influenced, by an item of software, the software has the same classification as the medical device.	<b>The TGA proposes to classify software that does not exclusively drive or influence the device based on its intended purpose</b> to ensure the classification is appropriate to the current use and risks posed to the patient and this also aligns with the EU rule.

1. **Independent** IVD Software has its own intended medical purpose. These devices are currently classified on their own, based on their intended purpose.





# Proposed changes with impact

## G. Software

2. IVD software intended to **drive or influence** the use of an IVD device. This software may be an integral component of the IVD device or may be supplied separately.
  - a. **IVD software exclusively drives or influences an instrument:** It has the same classification as the IVD device.
  - b. **Software does more than only driving or influencing an IVD device:** It has analytical or interpretative functionality and should be classified based on its own intended purpose and risk.





# Proposed changes with impact

## G. Software

- **Impact:** Re-classification of some IVD software which does more than only driving or influencing an instrument; i.e. has analytical/interpretive functions and generates new diagnostic information.
- **Examples:**
  - AI-driven cervical smear analysis software (Class 3)
  - Flow cytometry analysis software with interpretive function that generates new diagnostic information (Class 3)
  - Digital imaging viewer software with subsequent analysis, such as cell identification (Class 2)
  - Software driving/influencing an ELISA microplate washer (Class 1)





# Questions

**Question 1:** Proposed changes to classification rules and principles that have an impact on approved products

- (a)** Do you agree with the proposals to change the Australian classification rules and principles as specified in Section A, noting the changes are reflective of the regulatory scrutiny based on the associated health risks?
- (b)** If no, which of the proposed changes do you not agree with? Please provide your reasons.
- (c)** Are there any other classification rules and principles, relating to the IVD medical devices, that need to be considered as part of this proposal?

# Refresher – How to use Slido



## Through the Slido application in Webex



- Click on the Apps icon
  - Select Slido
- Open the Q&A tab to ask questions
- Live Poll (use survey tab when prompted)



## Using the QR code



Scan the QR code to access Slido from your mobile device



# Proposed changes

B. Classification changes with **no impact** on approved IVDs



Australian Government  
Department of Health and Aged Care  
Therapeutic Goods Administration



# Proposed changes

## B. Classification changes with **no impact** on approved IVDs

- **Purpose**

To improve clarity and capture emerging technologies

- **Example**

Adding 'Cell administration' for CAR T-cell therapies

- **Impact**

No impact on approved IVDs anticipated



Australian Government  
Department of Health and Aged Care  
Therapeutic Goods Administration





## Key proposed changes:

- Adding 'suspected high risk of propagation'
- Including 'cell administration'
- Adding 'embryo'
- Including 'individual's offspring'
- Removing the statement 'the selection of patients'
- Removing 'imminent/immediate'
- Replacing 'specific characteristics' with 'no critical characteristics'





## Questions

**Question 2:** Proposed changes to classification rules and principles that have no impact on approved products

- (a) Do you agree with the proposals to adopt certain terminology in the Australian classification rules as specified in Appendix A, noting the changes are to improve clarity?
- (b) If no, which of the proposed changes do you not agree with? Please provide your reasons.
- (c) Do you agree the proposed changes in Appendix A, would not result in any impact on existing ARTG entries of IVD medical devices?
- (d) Are there any other classification rules, relating to the IVD medical devices, that need to be considered as part of this proposal?

# Classification rules proposed to retain

## Differences between EU IVDR and Aus classification rules

### Examples:

- SARS-CoV-2 IVDs
- Influenza IVDs
- HIV monitoring IVDs



Australian Government  
Department of Health and Aged Care  
Therapeutic Goods Administration



# Proposed changes

C. Definition changes with **no impact** on approved IVDs



Australian Government  
Department of Health and Aged Care  
Therapeutic Goods Administration



# Proposed changes

## C. Definition changes with **no impact** on approved IVDs

- **Purpose**

To improve clarity and capture emerging technologies

- **Example**

Including 'predisposition to a medical condition or a disease' in the IVD device definition

- **Impact**

No impact on approved IVDs anticipated



Australian Government  
Department of Health and Aged Care  
Therapeutic Goods Administration





## Key proposed changes:

- **Including** IVD-specific definitions: *'Performance Evaluation'*, *'Analytical Performance'*, *'Calibrator'*, and *'Control Material'*
- **Adding** the following purposes to the definition of IVD device:
  - Concerning the predisposition to a medical condition or a disease
  - To define or monitor therapeutic measures
- **Removing** the following statements from the definition of IVD device:
  - Not intended for general laboratory use; and
  - Manufactured, sold or presented for use as an IVD medical device.
- **Adding** **'not intended for self-testing'** to the definition of point-of-care testing (PoCT)
- **Replacing** 'a particular medicine' with **'corresponding medicine or biological products'** in CDx definition



# Questions

## **Question 3:** Proposed changes to the IVD definitions

- (a)** Do you agree with the proposal to amend the Australian definitions as specified in Appendix B?
- (b)** If no, which of the proposed changes do you not agree with? Please provide your reasons.
- (c)** Are there any other definitions, relating to the IVD medical devices, that need to be considered as part of this proposal?

# Impacts

## What would change for sponsors?

- Verify the classification of their included devices;
- Ensure to have the supporting evidence;
- Apply for reclassification of their impacted devices in accordance with the transition arrangements.

## What would change for manufacturers?

- Reassess the compliance of their IVD medical devices with any revised classification rules;
- Ensure to have all appropriate evidence to comply with any relevant regulatory requirements.



# Transition arrangements

- Transition timelines for re-classification of impacted existing applications and ARTG entries to be six months after the current EU IVDR transition deadlines.
- Deadlines for each Class of IVDs:
  - Until 30 June **2028** for Class **4** IVDs
  - Until 30 June **2029** for Class **3** IVDs
  - Until 30 June **2030** for Class **2** IVDs



Australian Government  
Department of Health and Aged Care  
Therapeutic Goods Administration





## Question

### **Question 4:** Transition period

- (a) Do you agree with the proposal to apply a 6-month transition period after the EU IVDR transition timelines for the proposed Australian amendments to take effect?
- (b) Provide reasons for your position (optional).




# How did we go?

Take a moment to complete our survey, and we'll be back with you shortly for Q&A



Australian Government  
Department of Health and Aged Care  
Therapeutic Goods Administration




Use the app in Webex



Use the QR code

# Questions?

Ask us through Slido



Use the app in Webex



Use the QR code



Australian Government  
Department of Health and Aged Care  
Therapeutic Goods Administration



Babak Latif

Senior Technical Evaluator and Policy Officer  
Devices In Vitro Diagnostics Section (DIVDS)  
Therapeutic Goods Administration (TGA)



Shraddha Swami

Director,  
Devices In Vitro Diagnostics Section (DIVDS)  
Medical Devices Authorisation Branch (MDAB)  
Therapeutic Goods Administration (TGA)

# Website and Reference links

Consultation page and online survey

[Consultation: Proposed changes to the IVD medical device classifications and definitions - Therapeutic Goods Administration - Citizen Space](#)

Consultation paper

[Consultation Proposed changes to the IVD medical device classifications and definitions.pdf](#)




**Australian Government**  
**Department of Health and Aged Care**  
Therapeutic Goods Administration

**tga.gov.au**

# Contact us

**Devices In Vitro Diagnostics Section  
(DIVDS)**

**[IVDs@tga.gov.au](mailto:IVDs@tga.gov.au)**



# Stay connected

[Subscribe to updates](#)

[Social media](#)



LinkedIn



X (Twitter)



YouTube



Instagram



Facebook

[www.tga.gov.au/about-tga/social-media](http://www.tga.gov.au/about-tga/social-media)

[www.tga.gov.au/news/subscribe-updates](http://www.tga.gov.au/news/subscribe-updates)



Australian Government

Department of Health and Aged Care  
Therapeutic Goods Administration

[tga.gov.au](http://tga.gov.au)





**Australian Government**

---

**Department of Health and Aged Care**  
Therapeutic Goods Administration